NASDAQ:KALV - Kalvista Pharmaceuticals Stock Price, Forecast & News

Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) posted its quarterly earnings data on Tuesday, December, 3rd. The specialty pharmaceutical company reported ($0.33) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.55) by $0.22. The specialty pharmaceutical company earned $3.92 million during the quarter, compared to analyst estimates of $3.23 million. Kalvista Pharmaceuticals had a negative return on equity of 25.70% and a negative net margin of 182.37%. View Kalvista Pharmaceuticals' Earnings History.

Kalvista Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Kalvista Pharmaceuticals.

4 analysts have issued twelve-month price objectives for Kalvista Pharmaceuticals' shares. Their forecasts range from $28.00 to $31.00. On average, they anticipate Kalvista Pharmaceuticals' stock price to reach $30.00 in the next year. This suggests a possible upside of 98.9% from the stock's current price. View Analyst Price Targets for Kalvista Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kalvista Pharmaceuticals.

Media stories about KALV stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kalvista Pharmaceuticals earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 725,700 shares, a drop of 17.3% from the January 15th total of 877,600 shares. Based on an average daily trading volume, of 137,400 shares, the days-to-cover ratio is presently 5.3 days. Currently, 5.8% of the shares of the company are short sold. View Kalvista Pharmaceuticals' Current Options Chain.

Some companies that are related to Kalvista Pharmaceuticals include Enanta Pharmaceuticals (ENTA), Portola Pharmaceuticals (PTLA), NextCure (NXTC), Myovant Sciences (MYOV), Opko Health (OPK), Akebia Therapeutics (AKBA), Karyopharm Therapeutics (KPTI), Dermira (DERM), Odonate Therapeutics (ODT), Applied Therapeutics (APLT), Gossamer Bio (GOSS), Cytokinetics (CYTK), Stoke Therapeutics (STOK), Endonovo Therapeutics (ENDV) and Kiniksa Pharmaceuticals (KNSA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kalvista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Inovio Pharmaceuticals (INO), Ritter Pharmaceuticals (RTTR), Crispr Therapeutics (CRSP), GALAPAGOS NV/S (GLPG) and Sarepta Therapeutics (SRPT).

Kalvista Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (9.35%), Pictet Asset Management Ltd. (3.49%), Franklin Resources Inc. (1.59%), Victory Capital Management Inc. (1.54%), Victory Capital Management Inc. (1.54%) and State Street Corp (1.30%). Company insiders that own Kalvista Pharmaceuticals stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Daniel B Soland, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par. View Institutional Ownership Trends for Kalvista Pharmaceuticals.

KALV stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Algert Global LLC, Bank of America Corp DE and Bank of New York Mellon Corp. Company insiders that have sold Kalvista Pharmaceuticals company stock in the last year include Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par. View Insider Buying and Selling for Kalvista Pharmaceuticals.

KALV stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., Victory Capital Management Inc., Victory Capital Management Inc., Ikarian Capital LLC, Pictet Asset Management Ltd., Public Sector Pension Investment Board and Janus Henderson Group PLC. Company insiders that have bought Kalvista Pharmaceuticals stock in the last two years include Albert Cha and Daniel B Soland. View Insider Buying and Selling for Kalvista Pharmaceuticals.

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KALV stock can currently be purchased for approximately $15.08.

Kalvista Pharmaceuticals has a market capitalization of $268.88 million and generates $16.13 million in revenue each year. The specialty pharmaceutical company earns $-20,820,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.View Additional Information About Kalvista Pharmaceuticals.

The official website for Kalvista Pharmaceuticals is http://www.kalvista.com/.

Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]